The Baseline Majority Is Learning to Read the Actuarial Fine Print

The letter arrived without fanfare, a routine notice of policy renewal, and it took Tomas Ferreira three readings to understand that his premiums had gone up because other people were going to live longer than he would. Across the insurance markets this summer, the actuaries have finished doing a sum the public is only beginning to grasp: as augmentation stretches the healthy lifespan of the enhanced minority past a hundred, the risk pools that everyone shares are being quietly re-sorted, and the un-augmented baseline majority — still nineteen in twenty humans — is landing on the wrong side of the math. Longevity products are being repriced around lives the augmented will live and the baseline will not. It is not written as discrimination; it is written as prudence, in tables no ordinary policyholder ever sees. "The fine print is where the century keeps its inequities," says consumer advocate Leila Farsakh, who has spent the summer teaching people to read their own renewals. The enhancement divide was supposed to be about who lives longer. It is turning out, just as sharply, to be about who pays for the difference.